에 대한 최신 뉴스 ImmunityBio (NASDAQ:IBRX) 주식

ImmunityBio

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

News

Movers

AMKR

BILI

BRFS

IBRX

IRTC

ITCI

OLLI

RKLB

TALO

이들 중형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 빌리빌리(NASDAQ:BILI)의 주가는 지난주 &#39;산구오: 무딩티엔샤(San Guo: Mou Ding Tian Xia)&#39; 발표 이후 23.32% 상승했다. 또한 JP모건 애널리스트 다니엘 첸(Daniel Chen)은 중국의 빌리빌리를 중립에서 비중확대로 상향 조정하고 21달러 가격 목표를 발표했다. 

빌리빌리와 올리즈 바겐은 지난주 최대 성과를 보인 10개 중형주 중 일부 (6월 16일-6월 22일)

ImmunityBio Inc

In a continued shift away from its cashierless Go convenience stores, Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) has reportedly shuttered three more locations in New York last week.
What Happened: Amazon has been steadily reducing its Go stores that use the &#8220;Just Walk Out&#8221; technology, with the latest closures, the total number of Go stores has come down to 17 nationwide, <a href="https://techcrunch.com/2024/10/04/amazon-closes-more-of-its-cashierless-convenience-stores/">reported</a> TechCrunch (<a href="https://www.theinformation.com/briefings/amazon-closes-three-more-go-convenience-stores">via</a> The Information) on Friday.
Last year in March also, the <a href="https://www.benzinga.com/news/23/03/31252375/amazon-prepares-to-cut-more-fluff-shut-8-amazon-go-stores-in-seattle-san-francisco-nyc">company had shut down eight</a> Go stores in Seattle, San Francisco, and New York.
Earlier this year, the company removed the&nbsp;Just Walk Out technology from&nbsp;its grocery stores, focusing&nbsp;more on smaller grab-and-go shops. It also opened a new Go store in Washington.
The e-commerce giant also continues to license the&nbsp;Just Walk Out technology to&nbsp;third-party convenience stores.
See Also:&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41149666/nvidias-blackwell-gpu-sets-new-ai-benchmark-with-over-100-system-configurations-ana?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Nvidia&#8217;s Blackwell GPU Sets New AI Benchmark With Over 100 System Configurations, Analyst Says</a>
Why It Matters: In 2016, Amazon launched its Just Walk Out feature, enabling customers to scan a QR code when entering a store, pick up items, and leave without going through a traditional checkout.
The system relies on cameras, sensors, and a remote team monitoring shoppers to accurately track purchases and complete transactions.
However, the experimental system has faced several challenges, including long delays in finalizing transactions—sometimes taking hours—and the high costs involved in installing the necessary cameras and sensors at each location.
Earlier this year, it was reported that Amazon replaced this <a href="https://www.benzinga.com/news/24/04/38055211/amazon-to-replace-just-walk-out-checkout-technology-with-smart-dash-carts">technology with a &#8220;smart-cart&#8221;</a> system called Dash Cart in its grocery stores.
Despite the closures, Amazon continues to focus on profitable ventures and efficiency gains. Earlier this month, Morgan Stanley analyst Brian Nowak reiterated <a href="https://www.benzinga.com/news/24/10/41169322/amazons-profitable-essential-merchandise-efficiency-gains-set-to-drive-growth-analyst">Amazon with an Overweight rating</a>, highlighting the company&#8217;s growth potential.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41087674/openais-searchgpt-set-to-disrupt-googles-search-empire-as-former-engineer-sounds-alarm-on-deteriorat?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">OpenAI&#8217;s SearchGPT Set To Disrupt Google&#8217;s Search Empire As Former Engineer Sounds Alarm On Deteriorating User Experience Amid Rising Competition</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Wikimedia

Tech

Media

AMZN

Amazon Shutters 3 More Cashierless Go Stores In New York: Report

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is on the verge of reaching a new all-time high, according to a prominent crypto analyst. The analyst suggests that Bitcoin must break through a significant resistance level to achieve this milestone.
What Happened: Bitcoin could reach a new peak if it surpasses the $64,000 resistance level.
Inmortal, a well-known trader, shared with his 216,300 followers on X that Bitcoin&#8217;s recent decline from around $66,000 to $60,000 might be forming a local bottom. He is considering going long on BTC if it demonstrates a swing failure pattern near $60,000 or gains acceptance above $63,000.
"Breakout above $64,000 = New ATH."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Breakout above 64k = New ATH<a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> <a href="https://t.co/mUvDN5sTyi">pic.twitter.com/mUvDN5sTyi</a>
&mdash; Inmortal (@inmortalcrypto) <a href="https://twitter.com/inmortalcrypto/status/1842200703810633835?ref_src=twsrc%5Etfw">October 4, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, another analyst, Kaleo, predicts a short-term dip to approximately $57,000 or $58,000 before a rebound. He expects Bitcoin to rise gradually over the next month, especially after the presidential election, advising traders to accumulate during this period.
"Bitcoin. Still looking like a quick little chop to $57,000 or $58,000, followed by a grind higher the rest of the month into a full send post election."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> / <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> Still looking like a quick little chop to 57 / 58, followed by a grind higher the rest of the month into a full send post election <a href="https://t.co/QX3wGjPNJQ">pic.twitter.com/QX3wGjPNJQ</a>
&mdash; K A L E O (@CryptoKaleo) <a href="https://twitter.com/CryptoKaleo/status/1841839257096208721?ref_src=twsrc%5Etfw">October 3, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41100361/remember-sbfs-i-didnt-stash-billions-away-the-latest-ftx-repayment-update-may-have-other-i?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Remember SBF&#8217;s &#8216;I Didn&#8217;t Stash Billions Away&#8217;? The Latest FTX Repayment Update May Have Other Ideas</a>
Why It Matters: The potential for Bitcoin to hit new highs comes amid a backdrop of strong market performance. Recently, <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41191566/bitcoin-ethereum-dogecoin-end-the-week-with-strong-gains-summer-lull-seasonality-over-q4-b">cryptocurrency markets</a> have been buoyed by positive labor market data, signaling the end of the summer lull and the start of a bullish fourth quarter.
Additionally, <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41185013/bitcoin-rebounds-above-61-500-and-80k-is-more-likely-than-40k-says-top-technical-analyst">technical analysts</a> have noted Bitcoin&#8217;s rebound above $61,500, suggesting that $80,000 is more likely than $40,000. This aligns with the current bullish sentiment, despite some bearish low-timeframe actions.
Furthermore, <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41172369/bitcoin-not-a-safe-haven-but-rising-trump-odds-could-fuel-a-rally-standard-chartered">Standard Chartered</a> has highlighted Bitcoin&#8217;s role as a hedge against traditional financial system issues, rather than geopolitical tensions. This perspective reinforces the notion that Bitcoin&#8217;s price movements are more influenced by financial market dynamics than geopolitical events.
Price Action: At the time of writing, Bitcoin is trading at $62,120, showing a 1.5% increase over the past 24 hours, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41166146/would-bitcoin-drop-if-a-war-in-the-middle-east-breaks-out-yes-but-theres-a-catch?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Would Bitcoin Drop If A War In The Middle East Breaks Out? Yes, But There&#8217;s A Catch</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

Bitcoin Could Hit New All-Time High If It Breaks Above This Resistance Level, Says Analyst

Elon Musk, CEO of SpaceX, has stated that the future of human exploration on Mars is contingent on the <a href="https://www.benzinga.com/topic/2024-election">re-election of former President</a> Donald Trump and the reduction of what he calls &#8220;smothering regulations."
What Happened: Musk, who has thrown his weight behind Trump, endorsed him yet again in the backdrop of <a href="https://www.benzinga.com/news/24/09/41018400/spacex-hits-back-at-faa-chief-for-pinning-starship-delays-on-safety-concerns-every-statement-he-made">SpaceX's struggles</a> with the Federal Aviation Administration, or FAA.
&#8220;Unless Trump wins and we get rid of the mountain of smothering regulations (that have nothing to do with safety!), humanity will never reach Mars. This is existential.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Unless Trump wins and we get rid of the mountain of smothering regulations (that have nothing to do with safety!), humanity will never reach Mars. This is existential. <a href="https://t.co/I9zZuzRvHi">https://t.co/I9zZuzRvHi</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1842250303762051263?ref_src=twsrc%5Etfw">October 4, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41157836/teslas-cybercabs-could-be-a-potential-ride-sharing-disruptor-says-analyst-heres-wha?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla&#8217;s &#8216;Cybercabs&#8217; Could Be A Potential Ride-Sharing Disruptor, Says Analyst</a>
This comes amid escalating tensions between SpaceX and FAA, with Musk <a href="https://www.benzinga.com/news/24/09/41041586/spacex-ceo-elon-musk-calls-for-resignation-of-faa-administrator-mike-whitaker">recently calling for the resignation</a> of FAA chief Mike Whitaker.
Musk&#8217;s company has criticized Whitaker for his defense of delays in SpaceX&#8217;s Starship launch vehicle, claiming that &#8220;every statement he made was incorrect.&#8221;
Why It Matters: The relationship between SpaceX and the FAA has been strained, with Musk accusing the FAA of favoritism towards Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) and proposing a <a href="https://www.benzinga.com/markets/equities/24/09/40912464/elon-musk-accuses-faa-of-fining-spacex-over-nonsense-that-doesnt-affect-safety-amazingly-no-star">$633,009 fine on SpaceX</a> for regulatory violations.
Whitaker has defended the FAA&#8217;s actions, citing safety concerns and regulatory compliance as reasons for the delay in SpaceX&#8217;s Starship launch. He also stated that <a href="https://www.benzinga.com/news/24/09/41016988/spacex-in-violation-of-texas-federal-law-on-some-matters-says-faa-agency-hits-back-at-elon-musks-roc">SpaceX did not adhere</a> to permitting and licensing requirements, which Musk criticized as obstructive.
These ongoing disputes have led Musk to argue that the future of space exploration depends on a political climate that favors deregulation. His recent tweet suggests that he sees a Trump victory as a necessary condition for this to happen.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41161763/european-telecom-giants-threaten-legal-action-against-elon-musks-starlink-over-potential-fcc-rule-ch?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">European Telecom Giants Threaten Legal Action Against Elon Musk&#8217;s Starlink Over Potential FCC Rule Change</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

SPACE

Politics

General

Elon Musk Says 'Humanity Will Never Reach Mars' Unless Trump Wins: 'This Is Existential'

Former Treasury Secretary Larry Summers has expressed disapproval of the Federal Reserve&#8217;s decision to <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead">cut interest rates last month</a>, terming it a misstep in the face of the latest US job growth data.
What Happened: On Friday, Summers took to X, formerly Twitter, and voiced his disagreement with the Federal Reserve&#8217;s decision to slash interest rates by 50 basis points in September.
He labeled this action as a &#8220;mistake,&#8221; particularly in light of the recent data that shows <a href="https://www.benzinga.com/trading-ideas/previews/24/10/41170128/jobs-report-preview-could-september-labor-data-shift-feds-interest-rate-path">U.S. job growth</a> exceeding all predictions.
&#8220;Today&#8217;s employment report confirms suspicions that we are in a high neutral rate environment where responsible monetary policy requires caution in rate cutting,&#8221; he said.
See Also: <a href="https://www.benzinga.com/news/24/08/40301145/lawrence-summers-calls-for-sec-investigation-into-unprecedented-vix-movement">Lawrence Summers Calls For SEC Investigation Into Unprecedented VIX Movement</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Today's employment report confirms suspicions that we are in a high neutral rate environment where responsible monetary policy requires caution in rate cutting. With the benefit of hindsight, the 50 basis point cut in September was a mistake, though not one of great consequence.…
&mdash; Lawrence H. Summers (@LHSummers) <a href="https://twitter.com/LHSummers/status/1842214555562258679?ref_src=twsrc%5Etfw">October 4, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41184080/us-economy-adds-254-000-new-jobs-in-september-smashes-expectations-unemployment-f">September jobs report</a> exceeded expectations, showing a 254,000 increase in U.S. payrolls and a surprising drop in the unemployment rate to 4.1%.
Wage growth also outpaced predictions, climbing 0.4% from the previous <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41187740/blowout-september-jobs-report-spurs-reactions-6-economists-say-aggressive-fed-rat">month and 4% over the past</a> year.
Joseph Brusuelas, principal and chief economist at RSM US LLP, highlighted the strong wage increases and dismissed recession concerns, pointing instead to a &#8220;mid-cycle economic expansion.&#8221;
Aditya Bhave, U.S. economist at BofA Securities, adjusted his November forecast to smaller rate cuts (25 basis points) due to the robust economic data.
Bhave predicted a terminal rate of 3.0%-3.25%, with the potential for it to rise further, given the unexpectedly strong productivity growth.
Before the September rate cut, Federal Reserve Chairman Jerome Powell had stated that future interest rate cuts would hinge on economic data. His comments at the time added <a href="https://www.benzinga.com/news/24/09/41102248/stocks-slip-as-powell-says-future-interest-rate-cuts-hinge-on-data-economy-is-in-solid-shape-we-inte">uncertainty to the market</a>, causing stocks to slip.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39875424/larry-summers-biden-quitting-shifts-focus-to-trumps-dishonesty-demagoguery-and-dangerousness-warns-e">Larry Summers: Biden Quitting Shifts Focus To Trump&#8217;s &#8216;Dishonesty, Demagoguery, And Dangerousness&#8217; — Warns Ex-President&#8217;s Policies Will &#8216;Undermine Economic Security Of Tens Of Millions&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Economics

Federal Reserve

Former Treasury Secretary Larry Summers Slams Fed's September Rate Cut Saying It Was A Mistake: 'Today's Employment Report Confirms Suspicions That...'

Department of Transportation Secretary Pete Buttigieg took aim at Elon Musk on Friday over allegations that federal authorities hindered flights delivering aid to <a href="https://www.benzinga.com/topic/hurricane-helene">Hurricane Helene</a> victims.
What Happened: Musk posted a screenshot implying that airspace was &#8220;shut down&#8221; and the Federal Aviation Administration (FAA) was &#8220;throttling flights.&#8221;
Musk voiced his frustration, stating, &#8220;The level of belligerent government incompetence is staggering!!&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Just received this text 20 mins ago. The level of belligerent government incompetence is staggering!! <a href="https://t.co/wWbBR7FfUo">pic.twitter.com/wWbBR7FfUo</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1842252268856324160?ref_src=twsrc%5Etfw">October 4, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In response, Buttigieg refuted these claims, asserting that the FAA does not obstruct legitimate rescue and recovery flights. He extended an invitation to Musk to discuss any issues directly, saying, &#8220;If you're encountering a problem give me a call.&#8221;
Following their public exchange, Musk expressed gratitude for a private conversation with Buttigieg, indicating a desire to resolve the matter. &#8220;Thanks for the call. Hopefully, we can resolve this soon,&#8221; Musk wrote, though the details of their discussion remain undisclosed.
See Also: <a href="https://www.benzinga.com/news/24/10/41157285/elon-musks-mom-chimes-in-after-son-says-he-cant-handle-4-years-of-seeing-and-hearing-kamala-harris-a?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s Mom Chimes In After Son Says He Can&#8217;t Handle 4 Years Of &#8216;Seeing And Hearing&#8217; Kamala Harris And Tim Walz</a>
Musk also posted a video showing SpaceX engineers trying to deliver Starlink terminals.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">SpaceX engineers are trying to deliver Starlink terminals &amp; supplies to devastated areas in North Carolina right now and <a href="https://twitter.com/fema?ref_src=twsrc%5Etfw">@FEMA</a> is both failing to help AND won't let others help. This is unconscionable!! They just took this video a few hours ago, where you can see the level of… <a href="https://t.co/abpOsfNenF">pic.twitter.com/abpOsfNenF</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1842284913279586447?ref_src=twsrc%5Etfw">October 4, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The backdrop of this exchange is the ongoing recovery efforts following Hurricane Helene, which has significantly impacted the region.
<a href="https://www.benzinga.com/news/24/10/41138209/elon-musks-spacex-to-give-free-starlink-access-to-hurricane-helene-victims">Musk&#8217;s SpaceX</a> has been proactive in offering free Starlink access to affected areas, aiming to facilitate communication and aid efforts. This move was part of a broader initiative to deploy a software update ensuring Starlink systems operate without payment in hurricane-affected zones.
Furthermore, the hurricane season has been notably active, with <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41145534/hurricane-helene-adds-to-most-active-quarter-for-power-outages-driving-back-up-gene">Hurricane Helene</a> contributing to widespread power outages, affecting millions. This has driven demand for backup generators, as noted by analysts observing increased consumer interest in such products.
Amidst these challenges, the <a href="https://www.benzinga.com/news/24/10/41195085/white-house-counters-gop-accusations-of-fema-funds-misuse-denies-disaster-relief-funding-was-used-fo">White House</a> has been countering accusations from Republicans regarding the misuse of FEMA funds in the aftermath of the hurricane. These claims have been strongly denied, with officials labeling them as falsehoods.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41195023/kamala-harris-meets-arab-american-leaders-angry-at-us-for-supporting-israel-in-ongoing-conflict-in-g">Kamala Harris Meets Arab American Leaders Angry At US For Supporting Israel In Ongoing Conflict In Gaza: Report</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Gage Skidmore via Flickr

Pete Buttigieg And Elon Musk Clash Over Hurricane Aid Flight Claims

The White House has refuted Republican claims of Federal Emergency Management Agency (FEMA) funds mismanagement following Hurricane Helene.
What Happened: On Friday, Andrew Bates, the senior deputy press secretary, issued a memo accusing Republicans of propagating &#8220;bald-faced lies&#8221; about the post-Hurricane Helene cleanup efforts, <a href="https://thehill.com/homenews/administration/4916014-federal-response-criticized/">reported</a> The Hill.
Republicans, including former President Donald Trump, have claimed&nbsp;that disaster relief funding was&nbsp;spent on migrants, criticizing the administration&#8217;s hurricane response.
Bates denied these allegations, saying, &#8220;No disaster relief funding at all was used to support migrants housing and services. None. At. All.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/10/41156066/elon-musk-cant-contain-his-joy-after-california-deepfakes-law-supported-by-gavin-newsom-blocked-by-c?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Can&#8217;t Contain His Joy After California Deepfakes Law Supported By Gavin Newsom Blocked By Court: &#8216;Yay!&#8217;</a>
He stated that Congress appropriates the funding for migrant support to Customs &amp; Border Protection, and FEMA merely administers it.
Bates also noted&nbsp;that FEMA has already provided&nbsp;over&nbsp;$45 million in direct financial&nbsp;assistance to individuals and families&nbsp;affected by the storm. He cautioned against the potential harm of spreading false information, especially&nbsp;when people are in need.
On the same day, FEMA also released a fact-checking page, confirming that &#8220;no money has been diverted&#8221; and that it has sufficient funds&nbsp;for immediate response and recovery&nbsp;needs.
Why It Matters: Hurricane Helene, which hit on Sept. 26, caused significant damage and <a href="https://www.benzinga.com/news/24/10/41126631/hurricane-helene-devastation-the-latest-on-damage-companies-affected">left nearly 800,000 people</a> without power. The storm claimed more than 130 lives and caused widespread power outages, affecting over two million customers of Duke Energy Corp.
As a result of the hurricane, there was a surge in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41145534/hurricane-helene-adds-to-most-active-quarter-for-power-outages-driving-back-up-gene">demand for backup and portable</a> power generators.
President Joe Biden has urged Congress to reconvene from recess to approve more funding for recovery efforts, though lawmakers aren't scheduled to return until Nov. 12.
His administration has already sent over 4,800 federal personnel to aid in the response, and the president has authorized the deployment of up to 1,000 troops to assist with North Carolina's recovery, the report noted.
Biden visited North Carolina on Wednesday, followed by trips to Florida and Georgia on Thursday to assess the damage and meet with local leaders.
Previously, Republican presidential nominee Trump allegedly took credit for the deployment of Elon Musk-led Starlink satellites to aid communication restoration in areas affected by Hurricane Helene.
However, FEMA contradicted his statement, saying that the decision was already in <a href="https://www.benzinga.com/news/24/10/41110218/trump-says-he-spoke-with-elon-musk-for-starlink-deployment-to-aid-hurricane-helene-affected-areas-bu">place before Trump's alleged</a> involvement.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41136119/vance-vs-walz-flash-poll-picks-this-candidate-as-tuesdays-debate-winner-but-he-falls-short-in-favora?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Vance Vs. Walz: Flash Poll Picks This Candidate As Tuesday&#8217;s Debate Winner, But He Falls Short In Favorability Rating</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Flickr

White House Counters GOP Accusations Of FEMA Funds Misuse, Denies Disaster Relief Funding Was Used For Migrant Housing: 'Bald-Faced Lies'

Chinese electric vehicle startup Nio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) announced late Friday that it has struck a partnership with one of its strategic investors to foray into the <a href="https://www.benzinga.com/markets/asia/24/06/39213251/asia-mena-gaming-markets-reach-85-5b-in-2023-see-future-projections">Middle East and North Africa</a>.
What Happened: Nio has tied up with Abu Dhabi-based CYVN Holdings to launch the Nio MENA in a bid to launch Nio-branded vehicles and vehicles from its subsidiary in the region, the Shanghai-based company said in a statement. This, according to the company, will expand its footprint and integrate further into the &#8220;global smart EV ecosystem.&#8221;
CYVN Holdings will support Nio with strategic investments for the expansion, which will start with UAE.
The company also plans to establish a state-of-the-art R&amp;D center in Abu Dhabi, the capital city of UAE. This center will focus on &#8220;autonomous driving and artificial intelligence advancements, reinforcing NIO's global R&amp;D capabilities and fostering technological innovation in the MENA region.&#8221;
Nio and CYVN Holdings plan to collaborate on a new EV project that will involve research, manufacturing, and future product launches. The EV startup would also work with its partners in Egypt to expand EV manufacturing in the country.
In <a href="https://www.benzinga.com/markets/asia/23/12/36281426/nio-stock-up-premarket-after-securing-2-2b-strategic-investment" target="_blank" rel="noreferrer noopener">December Nio closed a $2.2 billion equity investment from</a>&nbsp;CYVN Investments RSC Ltd.
 Jassem Mohamed Obaid Bu Ataba Alzaabi, Chairman of CYVN Holdings, said, &#8220;This partnership is a testament to our mutual commitment to fostering the strength of our strategic collaborations and achieving transformative goals in the smart mobility sector.&#8221;
Nio&#8217;s founder, Chairman and CEO William Li said, &#8220;Our collaboration with CYVN Holdings is a cornerstone in our strategy to enhance global accessibility to smart electric vehicles and to push the boundaries of technological innovation.&#8221;
See Also: <a href="https://www.benzinga.com/money/best-electric-vehicle-stocks">Best EV Stocks</a>
Why It&#8217;s Important: Nio is a manufacturer of premium EVs and it has recently entered the low-end of the market with its Onvo brand. Deliveries of the first vehicle launched by the sub-brand, codenamed&nbsp;L60, began in late September, and early uptake has been fairly strong.
This week, Nio reported <a href="https://www.benzinga.com/markets/equities/24/10/41114350/chinese-ev-trio-nio-xpeng-li-auto-surge-higher-in-tuesdays-premarket-whats-going-on">strong September and record third-quarter deliveries</a> despite the tough domestic EV market conditions marked by lackluster demand and cutthroat competition. 
In late-September, the company said a trio of domestic strategic investors agreed to invest an aggregate of 3.3 billion yuan ($470.64 million) in cash in its subsidiary Nio China. Nio on its part said it would invest 10 billion yuan (about $1.43 billion) in cash to subscribe to the newly issued shares of Nio China.&nbsp;The latest investments would infuse the much-needed financing to pursue it expansion both in China and overseas. 
Nio&#8217;s prospects in China also appear bright, given China has decided to copiously stimulate the domestic economy, potentially arming consumers with the much-needed cash to splurge.
The company currently sells EVs in European countries such as Norway, Sweden, Germany, and the Netherlands. The MENA partnership comes as the <a href="https://www.benzinga.com/markets/equities/24/10/41182675/tesla-byd-and-other-ev-stocks-to-watch-as-eu-votes-to-approve-tariffs-on-chinese-ev-imports">European Commission has voted in favor of up to 45% tariffs on imported Chinese EVs.</a>
Price Action: Nio ended Friday&#8217;s session up 1.04% at $6.77, according to <a href="https://benzinga.grsm.io/register174">Benzinga Pro data.</a>
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="http://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41182930/china-was-tipping-into-a-japan-style-lost-decade-of-deflation-and-stagnation-before-late-septemb">China Was Tipping Into A Japan-Style &#8216;Lost Decade&#8217; Of Deflation And Stagnation Before Late-September Stimulus Announcements, Says Legal Expert</a></li>
</ul>
Photo courtesy: Nio

Equities

Tesla Rival Nio Accelerates Global Expansion, To Launch EVs in Middle East Amid EU Tariff Concerns

Democratic Presidential nominee Kamala Harris has reportedly engaged with Arab American and Muslim leaders in Flint, Michigan, amid rising tensions over <a href="https://www.benzinga.com/news/24/06/39562547/us-has-sent-thousands-of-hellfire-missiles-and-2-000-pound-bombs-to-israel-amid-ongoing-war-with-ham">U.S. support for Israel&#8217;s conflicts</a> in Gaza and Lebanon.
What Happened: On Friday, Harris met with representatives from Emgage Action,&nbsp;the American Task Force on&nbsp;Lebanon, and long-time associate Hala Hijazi, reported Reuters, citing two sources.
The meeting is part of a broader effort to reconnect&nbsp;with Muslim and Arab voters,&nbsp;who were instrumental in securing a Democrat win in 2020 but may reconsider their support for Harris in the next election.
Harris addressed the upcoming election and the ongoing Middle East conflicts&nbsp;during the meeting.
She expressed&nbsp;concern over the&nbsp;suffering in Gaza, civilian casualties, and displacement in Lebanon,&nbsp;and discussed efforts to end&nbsp;the war and prevent a regional conflict, the report noted.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/10/41135574/elon-musk-comments-on-jd-vance-tim-walz-debate-after-user-favors-them-over-trump-and-harris-they-wer?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Comments On JD Vance-Tim Walz Debate After User Favors Them Over Trump And Harris: &#8216;They Were Civil&#8217;</a>
Wa&#8217;el Alzayat, CEO of Emgage&nbsp;Action, said they &#8220;asked Vice President Harris to impress upon President Biden the urgency of bringing an immediate end to the violence&#8221; in Gaza and Lebanon.
However, some Arab Americans believe Harris&#8217; reluctance&nbsp;to distance herself from President&nbsp;Biden&#8217;s Middle East policies could cost her in the upcoming election.
A recent poll&nbsp;by the Arab American Institute&nbsp;found Harris and Trump at&nbsp;roughly even levels of support&nbsp;among Arab Americans.
Why It Matters: The meeting comes amidst a backdrop of escalating tensions in the Middle East.
Last month, <a href="https://www.benzinga.com/news/24/09/40920151/china-slams-us-for-shielding-israel-blocking-gaza-ceasefire-efforts-as-war-nears-1-year">China accused the U.S.</a> of shielding Israel and obstructing ceasefire efforts in the Gaza conflict. &#8220;Had the US not shielded one side time and again, multiple resolutions of this council would not have been flagrantly rejected and defied.&#8221;
Later that month,&nbsp;senior U.S. officials <a href="https://www.benzinga.com/news/24/09/40955425/top-us-officials-skeptical-of-israel-hamas-cease-fire-and-hostage-deal-before-bidens-term-ends-repor">expressed skepticism about a ceasefire</a> and hostage-release deal between Israel and Hamas.
Meanwhile, Israel continued its <a href="https://www.benzinga.com/general/politics/24/09/41056542/israel-plans-to-disrupt-arms-delivery-from-iran-to-lebanon-in-motion-as-palestinian-president-cr">military operations in Lebanon and Gaza</a>.
Earlier in the year, Harris had urged Israeli Prime Minister Benjamin Netanyahu to help establish a Gaza ceasefire, a move that was <a href="https://www.benzinga.com/news/24/08/40417063/trump-says-he-encouraged-netanyahu-to-end-gaza-war-while-critizing-kamala-harris-for-demanding-cease">later criticized by</a> Republican presidential candidate Donald Trump.
&#8220;I will give Israel the support that it needs to win but I do want them to win fast,&#8221; Trump reportedly said in August.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/commodities/24/10/41151338/biden-the-master-oil-trader-part-iv-president-loads-up-on-millions-of-barrels-to-refill-emerg?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Biden The Master Oil Trader Part IV? President Loads Up On Millions Of Barrels To Refill Emergency Stash In &#8216;One Of The Best Oil Trades In History&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Kamala Harris Meets Arab American Leaders Angry At US For Supporting Israel In Ongoing Conflict In Gaza: Report

RPHM

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

CFRA analyst Jonathan Sakraida maintains Ingersoll Rand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) with a Hold and raises the price target from $85 to $95.

Price Target

Analyst Ratings

CFRA Maintains Hold on Ingersoll Rand, Raises Price Target to $95

Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has outperformed the market over the past 10 years by 19.23% on an annualized basis producing an average annual return of 30.74%. Currently, Tesla has a market capitalization of $798.69 billion. 
Buying $100 In TSLA: If an investor had bought $100 of TSLA stock 10 years ago, it would be worth $1,446.78 today based on a price of $250.01 for TSLA at the time of writing.
<h3>Tesla's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728077784_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

TSLA

Here's How Much You Would Have Made Owning Tesla Stock In The Last 10 Years

The phrase "the one percent" gets tossed around a lot in conversations about wealth and inequality, whether in politics, protests, or everyday chats. But what does it mean to be in the top 1%? Let's break it down by income and net worth to get a clearer picture of <a href="https://www.benzinga.com/personal-finance/24/09/40711869/how-rich-are-you-heres-the-net-worth-that-defines-upper-middle-and-lower-class">who's part of this exclusive group.</a>
Don't Miss:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
</ul>
What Income Puts You in the Top 1%?
To be in the <a href="https://www.benzinga.com/personal-finance/24/07/39652328/your-income-might-be-upper-class-and-you-dont-know-it-heres-the-salary-needed-to-reach-elite-sta">top 1% of earners</a> in the U.S., a household must bring in at least $591,550 a year. For a single individual, the cutoff is $407,500. Remember, these numbers are averages and can vary depending on where you live. For example, earning that much in New York City might not stretch as far as it does in other parts of the country.
The Top 1% by Net Worth
When it comes to net worth, the threshold is even higher. To be part of the top 1% in the U.S., a household's net worth needs to be at least $13.6 million. This measure includes everything you own – homes, investments, savings – minus debts.
Wealth tends to be a lot more unevenly distributed than income. Many households have little to no net worth, while the top tier sits on massive wealth. That's why net worth often gives a clearer picture of someone's financial status than income alone.
Trending: Beating the market through ethical real estate investing' — t<a href="https://www.benzinga.com/money/invest-with-roots">his platform aims to give tenants equity in the homes they live in while scoring 17.17% average annual returns for investors – here&#8217;s how to join with just $100</a>
Income vs. Net Worth: Which Tells the Real Story?
So, which is more important, income or net worth? It depends on what you're trying to measure. Income is great for understanding how much someone earns in a year, but net worth is the better gauge for long-term financial stability and overall wealth. Someone with a high income might not have a high net worth if they spend a lot or have significant debt, while someone with a lower income but solid investments could be much wealthier.
How Many People Are in the 1%?
As of the latest numbers, there are around 1.3 million households and about 1.8 million individual workers who fall into the top 1% in the U.S. That's a small slice of the population but represents a significant share of the country's wealth and income.
Trending: Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
State-by-State Variations
The income required to be in the top 1% varies significantly across states. For example:
<ul>
<li>Connecticut has the highest threshold at $952,902</li>
<li>Massachusetts follows at $903,401</li>
<li>California comes in third at $844,266</li>
<li>On the lower end, Mississippi has a threshold of just $254,362</li>
</ul>
See Also: <a href="https://www.benzinga.com/money/irs-finalizes-10-year-rule-adv">IRS Finalizes 10-Year Rule For Retirement Withdrawals, Making Things &#8216;Even More Insanely Complicated&#8217;</a>
Understanding <a href="https://www.benzinga.com/personal-finance/24/08/40378006/exactly-how-much-money-do-you-need-to-be-rich-heres-a-look-at-the-numbers">who makes up this elite group</a> isn't just about how much you earn right now but also what you've built over time.&nbsp;
Maybe you're not in the top 1%, or maybe you are – everyone's situation is different. Either way, <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">talking with a financial advisor</a> can be really helpful. They can guide you on where you stand and how to make the best decisions for your financial future, whether you're growing your wealth or looking to manage what you've got.
Read Next:
<ul>
<li>Founder of Personal Capital and ex-CEO of PayPal<a href="https://www.benzinga.com/money/evergreen-money"> re-engineers traditional banking with this new high-yield account — start saving better today.</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Personal Finance

Are You Rich Enough To Be In The Top 1%? Here's Both The Income And Net Worth You Need to Rank Among The Wealthiest

STOCK RECEIVES 4TH SIGNAL IN LAST 5 TRADING SESSIONS FOR OVER 5% GAIN 
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="776" height="797" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/04200903/Screen-Shot-2024-10-04-at-4.09.32-PM.png" alt="" class="wp-image-1972" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/04200903/Screen-Shot-2024-10-04-at-4.09.32-PM.png 776w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/04200903/Screen-Shot-2024-10-04-at-4.09.32-PM-292x300.png 292w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/04200903/Screen-Shot-2024-10-04-at-4.09.32-PM-768x789.png 768w" sizes="(max-width: 776px) 100vw, 776px" /></figure>
Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:37AM on October 4th, a significant trading signal occurred for Meta Platforms Inc. as it demonstrated a Power Inflow at a price of $582.40. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Meta&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Meta&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for Meta, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data are brought to you by Benzinga APIs</a> and include firms, like <a href="https://finitusa.com/en/">Finit USA</a>, responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $582.40. The returns on the High price ($596.52) and Close price ($595.94) after the Power Inflow were respectively 2.4% and 2.3%%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case the high of the day and close were very close but that is not always the case
Past Performance is Not Indicative of Future Results

Signals

Tradepulse Power Inflow Alert: Meta Platforms Inc. Receives Signal And Climbs Over 2.4% On The Day

Throughout the last three months, 7 analysts have evaluated Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $59.57, a high estimate of $65.00, and a low estimate of $54.00. Witnessing a positive shift, the current average has risen by 17.56% from the previous average price target of $50.67.
<img src="https://www.benzinga.com/files/images/story/2024/1728075764_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Newmont is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Murphy</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$63.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Daniel Major</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>David Coleman</td>
<td>Argus Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$58.00</td>
<td>-</td>
</tr>
<tr>
<td>Tanya Jakusconek</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$59.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jackie Przybylowski</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$57.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Matthew Murphy</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Anita Soni</td>
<td>CIBC</td>
<td>Raises</td>
<td>Outperformer</td>
<td>$61.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Newmont. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Newmont compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Newmont's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Newmont's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NEM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Newmont analyst ratings.</a>
<h2>About Newmont</h2>
Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to produce roughly 6.9 million ounces of gold in 2024. However, after buying Newcrest, Newmont is likely to sell a number of its higher cost, smaller mines accounting for 20% of forecast sales in 2024. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at the end of December 2023.
<h3>Newmont's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Positive Revenue Trend: Examining Newmont's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 64.07% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Newmont's net margin excels beyond industry benchmarks, reaching 19.38%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.93%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Newmont's ROA stands out, surpassing industry averages. With an impressive ROA of 1.54%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Newmont's debt-to-equity ratio stands notably higher than the industry average, reaching 0.31. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 7 Analyst Ratings Have To Say About Newmont

During the last three months, 12 analysts shared their evaluations of Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $59.83, along with a high estimate of $70.00 and a low estimate of $40.00. Marking an increase of 13.42%, the current average surpasses the previous average price target of $52.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1728075755_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Lumentum Holdings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simon Leopold</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Tim Savageaux</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$50.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>George Notter</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Richard Shannon</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$54.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Dave Kang</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Alex Henderson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$70.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Lumentum Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Lumentum Holdings compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Lumentum Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LITE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lumentum Holdings analyst ratings.</a>
<h2>All You Need to Know About Lumentum Holdings</h2>
Lumentum Holdings Inc is a California-based technology firm. The company provides two types of optical and photonic products: optical components that are used in telecommunications networking equipment, and commercial lasers for manufacturing, inspection, and life-science lab uses. Its segments are Optical Communications and Commercial Lasers. The firm is also expanding into new optical applications, such as 3-D sensing laser diode for consumer electronics. It generates maximum revenue from the OpComms segment. The OpComms segment products include a wide range of components, modules, and subsystems to support customers including carrier networks for access (local), metro (intracity), long-haul, and submarine (undersea) applications.
<h3>Unraveling the Financial Story of Lumentum Holdings</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Lumentum Holdings faced challenges, resulting in a decline of approximately -16.86% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Lumentum Holdings's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -81.9%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Lumentum Holdings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -23.66%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Lumentum Holdings's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.21%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Lumentum Holdings's debt-to-equity ratio stands notably higher than the industry average, reaching 2.67. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LITE

Assessing Lumentum Holdings: Insights From 12 Financial Analysts

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Quanta Services and provided 12-month price targets. The average target is $297.0, accompanied by a high estimate of $348.00 and a low estimate of $256.00. This upward trend is evident, with the current average reflecting a 3.28% increase from the previous average price target of $287.57.
<img src="https://www.benzinga.com/files/images/story/2024/1728075736_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Quanta Services's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$348.00</td>
<td>$302.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$256.00</td>
<td>-</td>
</tr>
<tr>
<td>Marc Bianchi</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$280.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$319.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Gus Richard</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$264.00</td>
</tr>
<tr>
<td>Alex Rygiel</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$303.00</td>
<td>$286.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$302.00</td>
<td>$299.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$288.00</td>
<td>$287.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Quanta Services. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Quanta Services compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Quanta Services's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Quanta Services's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PWR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Quanta Services analyst ratings.</a>
<h2>Discovering Quanta Services: A Closer Look</h2>
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under three reportable segments: electric power, renewables infrastructure, and underground utility and infrastructure.
<h3>Quanta Services: A Financial Overview</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Quanta Services showcased positive performance, achieving a revenue growth rate of 10.81% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 3.36%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.91%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Quanta Services's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.2%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.58, Quanta Services adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

8 Analysts Assess Quanta Services: What You Need To Know

In the preceding three months, 12 analysts have released ratings for American Intl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $85.25, a high estimate of $93.00, and a low estimate of $77.00. Observing a 0.08% increase, the current average has risen from the previous average price target of $85.18. 
<img src="https://www.benzinga.com/files/images/story/2024/1728075681_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of American Intl Gr by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Zaremski</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$90.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$77.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Paul Newsome</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Michael Ward</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$87.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$81.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$93.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Michael Phillips</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Scott Heleniak</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$87.00</td>
<td>$87.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to American Intl Gr. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of American Intl Gr compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for American Intl Gr's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of American Intl Gr's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AIG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on American Intl Gr analyst ratings.</a>
<h2>Delving into American Intl Gr's Background</h2>
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. The company recently spun off its life insurance operations (Corebridge), but still retains a majority stake.
<h3>American Intl Gr: Financial Performance Dissected</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Negative Revenue Trend: Examining American Intl Gr's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -11.75% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: American Intl Gr's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -60.38%, the company may face hurdles in effective cost management.
Return on Equity (ROE): American Intl Gr's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -9.06%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.12%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.22, American Intl Gr adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: American Intl Gr In The Eyes Of 12 Experts

The U.S. Department of Justice (DOJ) is holding firm on its stance that medical marijuana users should not allowed to own a gun, citing safety risks.
In a recent filing, federal attorneys argued that the <a href="https://www.benzinga.com/markets/cannabis/24/06/39488414/cannabis-guns-kentucky-2nd-amendment-meet-the-atf-if-you-say-yes-to-medical-marijuana-the-answer">ban on gun ownership</a> for cannabis users is constitutional and should remain in place. 
This aligns with federal regulations barring gun access for individuals considered potentially dangerous, such as those who are mentally ill or under the influence, <a href="https://www.marijuanamoment.net/doj-says-allowing-a-pennsylvania-prosecutor-who-uses-medical-marijuana-to-possess-a-gun-would-be-dangerous/">reported</a> Marijuana Moment.
<h3 class="wp-block-heading">Pennsylvania Prosecutor Challenges Federal Gun Ban</h3>
This filing responds to <a href="https://www.benzinga.com/markets/cannabis/24/01/36750779/guns-and-weed-conflict-heats-up-pennsylvania-da-sues-feds-over-firearms-ban-for-medical-marijuan">a lawsuit</a> by Robert Greene, the District Attorney of Warren County, Pennsylvania, who is a registered medical marijuana patient. Along with the Second Amendment Foundation, Greene filed suit against the DOJ, Attorney General Merrick Garland and other federal agencies, arguing that the ban infringes on his right to bear arms for self-defense.
The DOJ&#8217;s filing, submitted to the U.S. District Court for the Western District of Pennsylvania, seeks to dismiss Greene&#8217;s suit. 
"Marijuana's physical and mental effects impair a person's judgment, including judgment about whether to use firearms," it says.
The next step for Robert Greene's case involves a federal court decision on his request for a preliminary injunction.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/03/37823911/cannabis-and-guns-legal-battle-heats-up-as-feds-block-weapons-sales-over-weed-smell-lawsuits-ens">Cannabis And Guns: Legal Battle Heats Up As Feds Block Weapons Sales Over Weed Smell, Lawsuits Ensue</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Contradictory Ruling In Texas Gun &amp; Cannabis Rights Case</h3>
Greene's case is not the only legal battle on this issue. In a separate case, the 5th U.S. Circuit Court of Appeals ruled that cannabis users cannot be barred from owning firearms.
The ruling arose from <a href="https://www.benzinga.com/markets/cannabis/24/08/40655441/cannabis-users-cannot-be-barred-from-gun-ownership-u-s-appeals-court-rules">the case</a> of Paola Connelly, a Texas resident whose right to bear arms was upheld despite her past marijuana use. "Marijuana user or not, Paola is a member of our political community and thus has a presumptive right to bear arms," U.S. Circuit Judge Kurt Engelhardt ruled.
The decision is significant because it aligns with <a href="https://www.benzinga.com/markets/cannabis/23/08/33719970/federal-court-strikes-down-gun-prohibition-for-cannabis-users-as-unconstitutional">a 2022 Supreme Court</a> decision stating that firearm laws should reflect historical gun ownership traditions.
While the DOJ has not commented on this ruling, it raises questions about how the federal government will address gun ownership rights among the millions of legal cannabis users nationwide.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/08/40655441/cannabis-users-cannot-be-barred-from-gun-ownership-u-s-appeals-court-rules">Cannabis Users Cannot Be Barred From Gun Ownership, U.S. Appeals Court Rules </a></li>
</ul>
Cover: AI generated image

Cannabis

Government

Regulations

Legal

Justice Department Defends Ban On Gun Ownership For Medical Cannabis Users

Investors with a lot of money to spend have taken a bullish stance on Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SBUX, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Starbucks.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 12%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $26,650, and 7, calls, for a total amount of $435,875.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $75.0 to $100.0 for Starbucks during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Starbucks's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Starbucks's whale activity within a strike price range from $75.0 to $100.0 in the last 30 days. 
<h3>Starbucks Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728074755_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$7.8</td>
<td>$7.7</td>
<td>$7.75</td>
<td>$100.00</td>
<td>$155.0K</td>
<td>4.2K</td>
<td style="text-align: right;">203</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.15</td>
<td>$8.1</td>
<td>$8.15</td>
<td>$95.00</td>
<td>$86.3K</td>
<td>1.3K</td>
<td style="text-align: right;">126</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$2.83</td>
<td>$2.75</td>
<td>$2.75</td>
<td>$100.00</td>
<td>$50.6K</td>
<td>10.5K</td>
<td style="text-align: right;">213</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$17.45</td>
<td>$17.3</td>
<td>$17.38</td>
<td>$80.00</td>
<td>$43.5K</td>
<td>6.6K</td>
<td style="text-align: right;">27</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$21.1</td>
<td>$20.45</td>
<td>$21.04</td>
<td>$75.00</td>
<td>$42.0K</td>
<td>174</td>
<td style="text-align: right;">12</td>
</tr>
</tbody>
</table>

<h3>About Starbucks</h3>
Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 38,000 stores across more than 80 countries as of the end of fiscal 2023. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.
In light of the recent options history for Starbucks, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Starbucks Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 5,418,853, with SBUX's price up by 1.13%, positioned at $96.64.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 27 days.</li>
</ul>
<h3>Expert Opinions on Starbucks</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $104.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Bernstein has elevated its stance to Outperform, setting a new price target at $115. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Starbucks, maintaining a target price of $105. 
&#x2A; An analyst from BMO Capital persists with their Outperform rating on Starbucks, maintaining a target price of $110. 
&#x2A; An analyst from Jefferies downgraded its action to Underperform with a price target of $76. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Starbucks with a target price of $118. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Starbucks, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

SBUX

Check Out What Whales Are Doing With SBUX

Financial giants have made a conspicuous bearish move on Dollar Tree. Our analysis of options history for Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) revealed 9 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 66% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $60,260, and 7 were calls, valued at $925,315.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $55.0 to $100.0 for Dollar Tree over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Dollar Tree stands at 686.0, with a total volume reaching 13,653.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Dollar Tree, situated within the strike price corridor from $55.0 to $100.0, throughout the last 30 days.
<h3>Dollar Tree 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728074750_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.83</td>
<td>$2.65</td>
<td>$2.69</td>
<td>$85.00</td>
<td>$416.9K</td>
<td style="text-align: right;">730</td>
<td>1.5K</td>
</tr>
<tr>
<td>DLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.81</td>
<td>$2.67</td>
<td>$2.69</td>
<td>$85.00</td>
<td>$269.0K</td>
<td style="text-align: right;">730</td>
<td>2.5K</td>
</tr>
<tr>
<td>DLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$9.3</td>
<td>$9.2</td>
<td>$9.25</td>
<td>$75.00</td>
<td>$71.2K</td>
<td style="text-align: right;">240</td>
<td>79</td>
</tr>
<tr>
<td>DLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.8</td>
<td>$2.78</td>
<td>$2.77</td>
<td>$85.00</td>
<td>$65.9K</td>
<td style="text-align: right;">730</td>
<td>2.9K</td>
</tr>
<tr>
<td>DLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.81</td>
<td>$2.75</td>
<td>$2.78</td>
<td>$85.00</td>
<td>$45.1K</td>
<td style="text-align: right;">730</td>
<td>2.7K</td>
</tr>
</tbody>
</table>

<h3>About Dollar Tree</h3>
Dollar Tree operates discount stores across the United States and Canada, with over 8,600 shops under its namesake banner and nearly 7,800 under Family Dollar. About 47% of Dollar Tree's sales in fiscal 2023 were composed of consumables (including food, health and beauty, and cleaning products), around 45% from variety items (including toys and homewares), and over 5% from seasonal items. The Dollar Tree banner sells most of its merchandise at the $1.25 price point and positions its stores in well-populated suburban markets. Conversely, Family Dollar primarily sells consumable merchandise (80% of the banner's sales) at prices below $10. About two-thirds of Family Dollar's stores are located in urban and suburban markets, with the remaining one-third located in rural areas.
After a thorough review of the options trading surrounding Dollar Tree, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Dollar Tree's Current Market Status</h3>
<ul>
<li>With a trading volume of 3,407,814, the price of DLTR is up by 2.63%, reaching $70.9.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 54 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Dollar Tree</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $80.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from BMO Capital has revised its rating downward to Market Perform, adjusting the price target to $68. 
&#x2A; An analyst from Melius Research downgraded its action to Hold with a price target of $70. 
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a In-Line rating on Dollar Tree with a target price of $78. 
&#x2A; An analyst from Loop Capital downgraded its action to Hold with a price target of $65. 
&#x2A; An analyst from Guggenheim persists with their Buy rating on Dollar Tree, maintaining a target price of $120. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Dollar Tree with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

DLTR

This Is What Whales Are Betting On Dollar Tree

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Initially, I had every intention to write a cookie-cutter assessment of intriguing <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>; that is, I wanted to say that enterprises within this specialized healthcare field will always be relevant as humans leverage advanced innovations to address vexing conditions and diseases. That remains true. However, the latest political paradigm shift warrants a different discussion.



Over the weekend, President Joe Biden announced that he would no longer seek reelection. Amid rising questions about his age and overall fitness, he has decided to concentrate fulfilling the tasks at hand. The Democrats will decide how they will handle the situation in the limited time available. In the meantime, Republican candidate Donald Trump likely has an easy road to the White House.



Assuming that a second Trump term is inevitable, investors will need to adjust their portfolios accordingly. Trump has billed himself as a sort of Mr. Deregulation. That may have significant implications regarding the viability of these specialized healthcare juggernauts. With that in mind, below are biotech stocks to consider.



<h2>Vertex Pharmaceuticals (VRTX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/06/vrtx-stock-1-300x169.jpg" alt="Vertex Pharmaceuticals (VRTX) logo visible on display screen"><div>Source: Pavel Kapysh / Shutterstock.com</div></div>Hailing from Boston, Massachusetts, Vertex Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/vrtx-stock-quote/">VRTX</a>) engages in the development and commercialization of therapies for <a href="https://finance.yahoo.com/quote/VRTX/profile/">treating cystic fibrosis</a> (or CF). It&rsquo;s a pioneer in this treatment area, featuring multiple approved drugs. Vertex is also exploring therapies for other conditions, including sickle cell disease and beta-thalassemia.



On a financial level, VRTX stock offers investors a solid growth opportunity combined with a stable platform. In the past four quarters, Vertex posted average earnings of $4.16 per share. This figure beat out the consensus view of $3.94, yielding an average earnings surprise of 5.65%.



If there is a &ldquo;weakness&rdquo; in Vertex&rsquo;s game, it&rsquo;s that VRTX isn&rsquo;t the most undervalued of opportunities. For example, shares trade hands at 12.58X trailing-year revenue. However, over the past year, this metric sat at 10.12X.



Nevertheless, the premium could be worth it. In fiscal 2024, experts believe sales may rise to $10.76 billion. That would be up 16.7% from last year&rsquo;s haul of $9.22 billion. And in fiscal 2025, revenue could pop up to $11.71 billion. It&rsquo;s an attractive idea for biotech stocks to buy.



<h2>Amgen (AMGN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/AMGN1600-300x169.jpg" alt="A magnifying glass zooms in on the website for Amgen Inc (AMGN)."><div>Source: Shutterstock</div></div>Based in Thousand Oaks, California, Amgen (NASDAQ:<a href="https://investorplace.com/stock-quotes/amgn-stock-quote/">AMGN</a>) discovers, develops, manufactures and delivers human therapeutics. It&rsquo;s probably best known for its drug <a href="https://finance.yahoo.com/quote/AMGN/profile/">Enbrel to treat plaque psoriasis</a>, rheumatoid arthritis and psoriatic arthritis. Amgen also offers a robust oncology unit along with therapeutics targeting cardiovascular disease.



Financially, Amgen attracts investors for its stability and predictability. Over the trailing 12 months (TTM), the company features a return on equity of 72.57%, which is well above industry standards. During the past four quarters, it posted an average earnings per share of $4.58. This figure beat the collective consensus view of $4.33, yielding an earnings surprise of 5.55%.



What&rsquo;s more, Amgen features a five-year monthly beta of 58% (or 0.58 if you prefer). That&rsquo;s well below the benchmark equity index&rsquo;s rating of approximately 100%. Therefore, AMGN stock provides slow-and-steady confidence for conservative investors.



By fiscal 2024, experts see sales rising to $33.04 billion, implying a growth rate of 25.5%. EPS may also rise 11.83% to $19.48. Overall, it makes a solid case for biotech stocks to buy.



<h2>Axsome Therapeutics (AXSM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/12/axsm-stock-300x169.jpg" alt="A magnifying glass zooms in on the Axsome Therapeutics, Inc. (AXSM) logo"><div>Source: Pavel Kapysh/Shutterstock.com</div></div>Headquartered in New York City, Axsome Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/axsm-stock-quote/">AXSM</a>) engages in the development of novel therapies for diseases involving the central nervous system. It&rsquo;s perhaps best known for developing Auvelity, which is a treatment for major depressive disorders. Also, it&rsquo;s working on a therapeutic to address migraines. The company also features solutions for Alzheimer&rsquo;s disease, narcolepsy and fibromyalgia.



Financially, Axsome is a bit of a mixed bag. In the past four quarters, the biotech incurred an average loss per share of $1.60. However, covering experts anticipated a loss of only $1.20. Therefore, Axsome suffered a negative &ldquo;earnings&rdquo; surprise of 33.5%. That&rsquo;s not great. Also, investors will note that its five-year beta stands at 125%. Therefore, it&rsquo;s more volatile than the benchmark index.



That said, AXSM stock trades at 15.68X trailing-year sales. While objectively high, this figure is lower than the metric seen between the first quarter of 2023 to Q1 2024 (23.34X). By year&rsquo;s end, analysts believe that sales could rise to $377.67 million, implying an almost 40% growth rate.



Also, the high-end estimate calls for $442.8 million. For speculators, this could be one of the biotech stocks to gamble on.



<h2>Intellia Therapeutics (NTLA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/12/ntla-stock-300x169.jpg" alt="Intellia Therapeutics (NTLA Stock) logo on a smartphone screen."><div>Source: rafapress / Shutterstock.com</div></div>A genome-editing company, Intellia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ntla-stock-quote/">NTLA</a>) focuses on the development of curative therapeutics. Currently, Intellia&rsquo;s mainline in-vivo program is called NTLA-2001, which aims to address transthyretin amyloidosis. It&rsquo;s one of the leaders in developing what&rsquo;s known as the CRISPR-based gene-editing platform. The business enjoys high potential but it&rsquo;s also high risk.



As you might imagine, Intellia isn&rsquo;t profitable, producing a loss per share of $1.34 in the past four quarters. The one positive here is that analysts expected a loss per share of $1.41. Therefore, the &ldquo;earnings&rdquo; surprise came out to 5%. Still, I wouldn&rsquo;t get too comfortable as the five-year beta for NTLA stock stands at a whopping 181%.



So, why bother talking about Intellia, especially when it&rsquo;s priced at a sky-high sales multiple of 43.24X? Primarily, it has to do with the potential of gene editing. If the Trump administration puts people in place that would lead to a relaxed regulatory environment, entities like Intellia may skyrocket.



Interestingly, analysts already believe that fiscal 2024 sales may hit $70.78 million. That&rsquo;s up 95.1% from last year. Politically, it could be one of the biotech stocks to watch.



<h2>Arcutis Biotherapeutics (ARQT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/medical-biotech-stocks1600-300x169.png" alt="Healthcare business graph data and growth, Medical examination and doctor analyzing medical report network connection on tablet screen. VANI stock"><div>Source: PopTika / Shutterstock.com</div></div>A biopharmaceutical company, Arcutis Biotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/arqt-stock-quote/">ARQT</a>) focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is called ARQ-151, which is a topical cream that addresses plaque psoriasis and atopic dermatitis. With <a href="https://www.aad.org/about/burden-of-skin-disease">skin disease imposing a social and economic burden</a>, Arcutis is one of the most relevant biotech stocks.



Financially, Arcutis is one of the relatively smaller entities. Currently, it&rsquo;s not profitable, with the company posting a loss per share of 73 cents in the past four quarters. However, this figure represented an improvement over analysts&rsquo; consensus view of 90 cents below parity. Therefore, the &ldquo;earnings&rdquo; surprise came out to 21.25%.



Investors should be warned that the five-year beta for ARQT stock stands at 118%. However, that&rsquo;s not terrible for a speculative asset. Also, its price-to-sales ratio of 7.49X is much lower than the 11.52X metric seen in Q1 2024.



By year&rsquo;s end, analysts are looking for a top-line print of $164.03 million. That&rsquo;s up a whopping 175.2% from last year&rsquo;s tally of $59.61 million. Thus, it&rsquo;s an enticing idea among biotech stocks to consider.



<h2>Madrigal Pharmaceuticals (MDGL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div>A clinical-stage biopharmaceutical firm, Madrigal Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mdgl-stock-quote/">MDGL</a>) focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH). Madrigal is an intriguing opportunity among biotech stocks because of the lack of solutions for NASH. Therefore, success in this clinical area could lead to a blistering run for MDGL stock.



And that&rsquo;s also where the politics of biotech becomes very interesting. If indeed Trump wins his second term in office, the green flag could fly regarding regulatory obstacles. For now, Madrigal is attempting to tread water. In the past four quarters, the company incurred a loss per share of $5.77. That&rsquo;s worse than the expected red ink of $5.27.



Right now, Madrigal is a pre-revenue enterprise. So, it&rsquo;s difficult to make a valuation assessment. What can be said is that experts believe by year&rsquo;s end that sales will pop to $80.75 million. By fiscal 2025, revenue could rise dramatically to $364.02 million. If so, that would imply a growth rate of 350.8%. For speculators, MDGL represents one of the biotech stocks to watch closely.



<h2>ImmunityBio (IBRX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div>Perhaps the riskiest idea on this list of biotech stocks, ImmunityBio (NASDAQ:<a href="https://investorplace.com/stock-quotes/ibrx-stock-quote/">IBRX</a>) is a clinical-stage enterprise that engages in the development of therapeutics and vaccines that bolster the natural immune system. The aim here is to defeat cancers and infectious diseases. It features a range of platforms, including fusion proteins, and DNA and RNA-based recombinant protein vaccines.



As with many other clinical-stage entities, ImmunityBio isn&rsquo;t profitable. In the past four quarters, the company incurred a loss of 27 cents per share. That was also worse than the collective consensus view of 21 cents in the red. Therefore, the negative &ldquo;earnings&rdquo; surprise came out to 33.63%. That&rsquo;s obviously not the most encouraging backdrop.



Last year, the company only generated revenue of $622,000. However, analysts believe that by the end of this year, sales could clock in at $71.55 million. If so, that would imply a growth rate of 11,403.2%. What&rsquo;s more, the high-side estimate calls for $107.8 million.



In the following year, sales could skyrocket to $277.38 million, up nearly 288% from projected 2024 sales. And the high side for that year comes out to $308.2 million.



On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/2024/07/7-biotech-stocks-to-keep-on-your-clinical-radar/">7 Biotech Stocks to Keep on Your Clinical Radar</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Biotech Stocks to Keep on Your Clinical Radar

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ImmunityBio (NASDAQ:<a href="https://investorplace.com/stock-quotes/ibrx-stock-quote/">IBRX</a>) just reported results for the second quarter of 2024.<ul><li>ImmunityBio reported earnings per share of -20 cents. This was below the analyst estimate for EPS of -17 cents.</li><li>The company reported revenue of $1.05 million.</li><li>This was 58.45% worse than the analyst estimate for revenue of $2.52 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ibrx-stock-earnings-immunitybio-for-q2-of-2024/">IBRX Stock Earnings: ImmunityBio Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

IBRX Stock Earnings: ImmunityBio Misses EPS, Misses Revenue for Q2 2024

ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Hold rating on ImmunityBio (IBRX – Research Report), with a price targ...

Piper Sandler Keeps Their Hold Rating on ImmunityBio (IBRX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bluebird Bio (BLUE – Research Report), ImmunityBio...

Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), ImmunityBio (IBRX) and Neurocrine (NBIX)

ImmunityBio's Anktiva: Promising, But Organizational Complexity Keeps Me Cautious

CG Oncology: Promising Data, But Looks Expensive

Amid Major Threats, Merck Stock Is A Sell

ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt

Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August

ABUS

ALPMF

ALPMY

AMGN

ANTX

ARQT

ATHA

AXSM

BAYRY

BAYZF

BBIO

BLUE

BMRN

CDTX

CGON

CRBU

CVAC

FGEN

GLYC

HLVX

INAB

LXRX

MDGL

NBIX

NTLA

PGEN

QURE

RAPT

RHHBY

RLAY

RPTX

SLRN

VIRX

VRTX

Press Releases

Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityBio: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update

ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors

SHAREHOLDER ALERT: Morris Kandinov Investigating IBRX, AGL, XPOF and AKRO; Shareholders are Encouraged to Contact the Firm

Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm

IMMUNITYBIO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc. - IBRX

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

ImmunityBio's ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

BTAI

EGRX

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Akero Therapeutics

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

CG Oncology

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Geron

IDEAYA Biosciences

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Janux Therapeutics

Keros Therapeutics

Kymera Therapeutics

Myriad Genetics

Novavax

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Soleno Therapeutics

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Zai Lab Limited - American Depositary Shares

Zai Lab

Piper Sandler

Jefferies

이들 중형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>빌리빌리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>)의 주가는 지난주 &#8216;산구오: 무딩티엔샤(San Guo: Mou Ding Tian Xia)&#8217; 발표 이후 23.32% 상승했다. 또한 JP모건 애널리스트 다니엘 첸(Daniel Chen)은 중국의 빌리빌리를 중립에서 비중확대로 상향 조정하고 <a href="https://www.benzinga.com//node/39418621" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">21</a>달러 가격 목표를 발표했다.</li>
<li>이뮤니티바이오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>)의 주가는 안크티바(ANKTIVA)가 여러 주에 걸쳐 <a href="https://www.benzinga.com//node/39417764" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">첫 번째 상용 투여량</a>을 투여한 보험 적용 범위를 발표한 이후 지속적인 강세로 22.36% 상승했다.</li>
<li>사솔(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>)은 회사가 법원에서 회사와 토탈에너지스 SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) 마켓팅에 유리한 판결을 내렸다고 발표한 후 주가는 20.89% 상승했다. 또한 손해배상금으로 38.9억 랜드, <a href="https://www.benzinga.com//node/39412202" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">이자로 약 2,300만 랜드</a>를 받았다.</li>
<li>지난주 올리즈 바겐 아울렛 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>)의 주식은 JP모건이 중립에서 <a href="https://www.benzinga.com/quote/OLLI/analyst-ratings">비중확대</a>로 평가를 올린 이후 15.25% 상승했다.</li>
<li>인트라-셀룰러 테라피스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>)는 회사가 루마테페론을 주요 우울 장애 환자를 위한 보조 요법으로 평가하고 <a href="https://www.benzinga.com//node/39382029" target="_blank" rel="noreferrer noopener">1차 및 주요 2차 평가변수를 충족</a>시키는 두 번째 3상 시험의 톱라인 결과를 발표한 후 주가는 13.18% 상승했다.      shares advanced 12.06% on overall strength in chip stocks. Also, B. Riley Securities analyst <a href="https://www.benzinga.com/quote/AMKR/analyst-ratings" target="_blank" rel="noopener">raised the price forecast</a> on the stock from $45 to $50.</li>
<li>앰코 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>)는 전반적인 칩주 강세로 주가는 12.06% 상승했다. 또한 B. 라일리 증권(B. Riley Securities)의 분석가는 주식 가격 <a href="https://www.benzinga.com/quote/AMKR/analyst-ratings" target="_blank" rel="noopener">예측</a>을 45달러에서 50달러로 높였다.</li>
<li>아이리듬 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>)는 회사가 이전에 공개한 <a href="https://www.benzinga.com//node/39411935" target="_blank" rel="noreferrer noopener">제조 자동화 계획</a>의 초기 단계를 시작한 후 기업의 이정표에 도달했다고 발표한 후 주가는 11.53% 증가했다.</li>
<li>로켓 랩 USA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)는 주가는 <a href="https://www.benzinga.com//node/39429411" target="_blank" rel="noreferrer noopener">일본 기업 신스펙티브(Synspective)</a>와 도쿄에서 10개 제품 출시 계약을 체결한 후 11.32% 상승했다.</li>
<li>브레드 파이낸셜 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>)는 에버코어 ISI 그룹(Evercore ISI Group)이 이 주식을 언더퍼폼(Underperform)에서 인-라인(In-Line)으로 평가를 올리고 목표 주가를 42달러에서 45달러로 <a href="https://www.benzinga.com/quote/BFH/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정한 </a>이후 10.81% 상승했다. 또한 또한 RBC 캐피털은 해당 주식에 대해 섹터 퍼폼(Sector Perform) 등급을 유지하고 목표 주가를 38달러에서 45달러로 높였다.</li>
<li>BRF S.A.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRFS#NYSE">BRFS</a>)의 주식은 10.69% 상승했다.</li>
</ol>
위키미디어 커먼즈를 통한 사진
기사 읽기: <a href="https://kr.benzinga.com/news/%ea%b2%8c%ec%9e%84%ec%8a%a4%ed%83%91%ea%b3%bc-%ec%9e%90%eb%b9%8c%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10%ea%b0%9c%ec%9d%98/" target="_blank" rel="noopener">게임스탑과 자빌은 지난주 최악의 성과를 보인 10개의 대형주 중 일부 (6월 16일-6월 22일)</a>

Comments

ImmunityBio

뉴스

에 대한 최신 뉴스 ImmunityBio (NASDAQ:IBRX) 주식

월요일, 6월 24, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌